The GPX2 gene increased the sensitivity of cell lines to kahalide (for treating breast cancer) and also increased the tolerance of cell lines to cisplatin (for treating breast cancer, bladder cancer, esophageal cancer, and head and neck cancer) and arsenic trioxide (for treating leukemia). This evidence concerns the gene GPX2 and esophageal cancer.